SUNRISE, Fla., May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc.
(OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative
medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U.S. Department of Justice at
the request of the U.S. Food and Drug Administration (FDA). The lawsuit seeks to stop U.S. Stem Cell Clinic and related
parties from performing a surgical procedure using stem cells from autologous adipose tissue, even when a physician and patient
agree that such a procedure is in the best interest of the patient. USRM believes that the patient and physician have the
right to decide whether or not to use a patient's own cells for a therapeutic purpose without federal government
interference.
U.S. Stem Cell, Inc. is a leader in the regenerative
medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its
lead, developmental product Adipocell™, as well as veterinary stem cell training and stem cell banking and creation
and management of stem cell clinics.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are
forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan",
"expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations
thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known
and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements
and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no
obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's
business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission
which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: 954.835.1500
Email: usstemcell@us-stemcell.com
View original content with multimedia:http://www.prnewswire.com/news-releases/us-department-of-justice-files-lawsuit-at-request-of-fda-to-stop-us-stem-cell-clinic-from-performing-autologous-stem-cell-procedure-300645973.html
SOURCE U.S. Stem Cell, Inc.